“GVM Quote Here”
Geoffrey is co-founder and Chief Innovation Officer for Indigo, as well as a Partner at Flagship Pioneering, where he focuses on inventing technologies and starting companies to address global challenges in nutrition, environmental sustainability, and medicine. He is also a co-founder of Seres Therapeutics (NASDAQ:MCRB), Kaleido Biosciences, Sienna Biopharmaceuticals (NASDAQ:SNNA), Axcella Health, and others.
Geoffrey previously served as Chief Executive Officer of Kaleido Biosciences and Chief Technology Officer at Seres Therapeutics, where he led the build-out of their human microbiome R&D platforms and the discovery of SER-109, the first clinically-validated Microbiome Therapeutic. He was also VP of Product Discovery at Axcella, where he led the discovery of two clinically-validated drug candidates.
Geoffrey has been recognized with numerous patent grants, awards, and publications. He is an inventor on over 200 patent applications and patents, and he has co-authored more than 20 peer-reviewed publications. Geoffrey has received a number of awards and honors, including: Business Insider’s 30 Biotech Leaders Under 40, the prestigious Lemelson-MIT Student Prize, awarded to the most innovative student at MIT, and the National Inventors Hall of Fame Graduate Student Prize. He was awarded a Ph.D. in Biomedical Engineering and Medical Physics from MIT; a M.S. in Bioengineering from the University of California, San Diego; and a S.B. in Chemical Engineering from MIT.
One who is first or among the earliest in any field of inquiry, enterprise or progress
To lead the way for (a group); guide
To be the first to open or prepare
To take part in the beginnings of; initiate
We are Flagship Pioneering.
Fueled by curiosity and a quest for new sources of future value, Flagship conceives, creates, resources and grows first-in-category life sciences companies. Our unique, systematic, hypothesis-driven innovation process empowers us simultaneously to explore the world’s biggest problems and to conceive disruptive scientific solutions. Our ventures deliver breakthrough medicines, maximize the potential of new agricultural practices, and power the world with innovative resources. We call this Pioneering.
We are entrepreneurial scientists dedicated to maximizing value. Through Flagship’s pioneering process, our team continuously envisions opportunity in unexplored spaces and realizes value for society through disruptive innovations and ventures. We start with two simple phrases— “what if?” and “if only….” We suspend disbelief and deliver solutions that transform lives and change the world. We leverage a broad network of leaders from academia, start-ups and large corporations to challenge, evolve and perfect ideas until a compelling value proposition emerges.
Since our founding in 2000, we have originated and fostered the development of more than 100 scientific ventures resulting in $20 billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents. Innovation is our currency. Our creativity, optimism, boundless energy, and curiosity fuel Flagship’s success.
We pioneer scientific ventures for life.
Indigo is a company dedicated to harnessing nature to help farmers sustainably feed the planet. With a vision of creating a world where farming is an economically desirable and accessible profession, Indigo works alongside its farmers to apply natural approaches, conserve resources for future generations, and grow healthy food for all. Utilizing beneficial plant microbes to improve crop health and productivity, Indigo’s portfolio is focused on cotton, wheat, corn, soybeans, and rice. The company, founded by Flagship Pioneering, is headquartered in Boston, MA, with additional offices in Memphis, TN, Research Triangle Park, NC, Sydney, Australia, Buenos Aires, Argentina, and São Paulo, Brazil. www.indigoag.com
Kaleido Biosciences is a clinical-stage biotechnology company that is developing the first therapeutic products to systematically shape the microbiome. The human microbiome is one of the most important frontiers in modern medicine. It plays a central role in numerous severe metabolic, inflammatory, and infectious diseases. Kaleido has discovered a broad new means of driving the central functions of the human microbiome with applications spanning a wide range of important diseases.
Our mission is to transform the lives of patients worldwide with revolutionary microbiome therapeutics.
Seres Therapeutics is creating a new class of medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis
New insights into the human microbiome are fundamentally reshaping how we understand and treat a wide range of diseases, creating new possibilities for patients not served by current approaches. We are a clinical biopharmaceutical company with a powerful platform to discover and develop drugs to treat diseases in multiple areas of medicine that arise from dysbiosis.
We pinpoint functional differences between a healthy and dysbiotic microbiome, and rationally design potential Ecobiotic® drugs. These therapeutics are ecological compositions made up of beneficial organisms that are designed to target functional deficiencies and reestablish keystone features of a healthy microbiome. Our discovery efforts currently span metabolic, inflammatory, and infectious diseases.
Founded: 2010 by Flagship Pioneering
Location: Cambridge, MA
Our Name: Seres is the plural noun of the word Sere, defined as the sequence of ecological communities that undergo succession
CEO: Roger Pomerantz, M.D.
Lead Program: SER-109 Phase 3 program for the prevention of recurrent Clostridium difficile infection; designated Breakthrough Therapy by FDA
Areas of focus: Infectious disease, metabolic diseases, inflammatory/immunology (including immuno-oncology)
INNOVATION IN MEDICAL DERMATOLOGY AND AESTHETICS
THE AXCELLA STORY
Axcella is combining endogenous metabolic modulators to develop powerful new medicines with the goal of addressing metabolic dysregulation by safely reprogramming cellular physiology with unprecedented multifactorial effects. Our AXA™ product candidates are designed to leverage the diversity and synergy of amino acid biology and target restoring health across a network of dysregulated pathways.
We are committed to researching and developing groundbreaking treatments for patients with unmet needs. Our AXA candidates are designed, optimized and studied using our platform. This innovative paradigm integrates preclinical studies and data from our human signal seeking and confirming studies* in a rapid, iterative process to generate candidates with a higher probability of success. Our platform has already produced a rich pipeline of multifunctional product candidates including programs in liver, muscle, CNS and other indications.